About zPREDICTA
zPREDICTA is a company based in San Jose (United States) founded in 2014 was acquired by Predictive Oncology in December 2021. zPREDICTA has raised $220 thousand across 2 funding rounds from investors including Predictive Oncology, Propel(x) and Y Combinator. The company has 3 employees as of December 31, 2022. zPREDICTA offers products and services including 3D Cell Culture Models and Tumor-Specific In Vitro Models. zPREDICTA operates in a competitive market with competitors including Yecuris, Xentech, Chengdu Zhongke Aoge Biotechnology, Sagres Discovery and Zebrafish Lab, among others.
- Headquarter San Jose, United States
- Employees 3 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zpredicta Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$220 K (USD)
in 2 rounds
-
Latest Funding Round
$100 K (USD), Seed
Jun 01, 2016
-
Investors
Predictive Oncology
& 2 more
-
Employee Count
3
as on Dec 31, 2022
-
Acquired by
Predictive Oncology
(Dec 01, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of zPREDICTA
zPREDICTA offers a comprehensive portfolio of products and services, including 3D Cell Culture Models and Tumor-Specific In Vitro Models.
Provides 3D models for evaluating anticancer agents in human-like tissue.
Enables testing of drug responses in organ-specific disease environments.
Funding Insights of zPREDICTA
zPREDICTA has successfully raised a total of $220K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in zPREDICTA
zPREDICTA has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Predictive Oncology, Propel(x) and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Deep technology startups are funded via equity crowdfunding platform.
|
Locked | Locked | Locked | |
|
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
Locked | Locked | Locked |
Investor details for zPREDICTA
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by zPREDICTA
Investment portfolio details for zPREDICTA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - zPREDICTA
Detailed financials for zPREDICTA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zpredicta Comparisons
Peer comparison for zPREDICTA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of zPREDICTA
zPREDICTA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Yecuris, Xentech, Chengdu Zhongke Aoge Biotechnology, Sagres Discovery and Zebrafish Lab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Humanized liver rodent models are developed for biology research.
|
|
| Locked | Locked | Locked |
Patient-derived xenograft models for preclinical oncology research are provided.
|
|
| Locked | Locked | Locked |
Xenotransplantation technology for human-compatible organs is developed.
|
|
| Locked | Locked | Locked |
Creates innovative mouse models to analyze genes causing cancer diseases.
|
|
| Locked | Locked | Locked |
Zebrafish assays are utilized for preclinical and environmental evaluations.
|
Detailed competitors of zPREDICTA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zpredicta
Complete news archive for zPREDICTA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about zPREDICTA
zPREDICTA was founded in 2014 and raised its 1st funding round 1 year after it was founded.
zPREDICTA is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
zPREDICTA is a funded company, having raised a total of $220K across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at zPREDICTA is 3.
Founded in 2014 and headquartered in San Jose, United States, tumor-specific in vitro 3D models are developed for applications in cancer drug screening. The proprietary PD-3D platform is utilized to replicate human in vivo conditions in assays. Reconstructed bone models under the rBone product line are offered for testing potential therapeutics in oncology. Operations focus on biotechnology services supporting pharmaceutical research and development.
zPREDICTA's top competitors include Yecuris, Chengdu Zhongke Aoge Biotechnology and Zebrafish Lab.
zPREDICTA offers 3D Cell Culture Models and Tumor-Specific In Vitro Models.
zPREDICTA has 3 investors. Key investors include Predictive Oncology, Propel(x), and Y Combinator.